YOLFTbeta
Steminent Biotherapeutics Inc.

Steminent Biotherapeutics Inc.

7729 · TWO · Healthcare / Biotechnology

230.50TWD-2.00 (-0.86%)

Price History

Full chart

Market Stats

Previous Close232.50
Open237.00
Day Range224.00 – 239.00
52-Week Range39.70 – 232.00
Volume741.13K
Market Cap18.72B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.97
Dividend Yield0.00%
Beta0.13
50-Day Avg110.28
200-Day Avg84.72

About

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It provides Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes consisting acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOLing-Mei Wang
  • HeadquartersNo. 12, Wenhu Street, Taipei, Taiwan, 11445, Taiwan
  • Websitehttps://steminent.com

Leadership

  • Ling-Mei WangChairman & GM
  • Yi-Chih LoDirector of Finance & Corporate Governance Officer and Accounting Supervisor
  • Mr. Jonathan KoSenior Vice President

Financials

Income Statement

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue51.47M2.12M636.00K941.00K0-
Growth (%)--95.88%-70.01%+47.96%-100.00%-
Cost of Revenue22.95M3.87M9.57M1.98M16.43M785.00K
Gross Profit28.52M-1.75M-8.93M-1.04M-16.43M-
Gross Margin55.41%-82.32%-1404.09%-110.10%--
Operating Expense71.47M73.85M89.28M130.42M145.87M-
Operating Income-42.95M-75.59M-98.21M-131.46M-162.29M-173.66M
Operating Margin-83.45%-3564.12%-15442.14%-13970.14%--
EBITDA-35.39M-111.54M-75.15M-115.39M-140.26M-141.08M
EBITDA Margin-68.76%-5258.98%-11815.72%-12262.17%--
Net Income-55.21M-124.20M-85.47M-129.23M-158.75M-174.04M
Net Income Margin-107.27%-5855.78%-13439.31%-13733.16%--
R&D44.25M48.09M55.41M67.73M110.38M115.28M
R&D as % of Total Revenue85.97%2267.33%8712.42%7197.24%--
Interest Expense790.00K1.33M898.00K1.78M1.92M2.15M
Interest Expense % of Total Revenue1.53%62.52%141.19%189.37%--

Balance Sheet

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets100.18M279.50M235.65M593.88M436.66M698.49M
Total Liabilities113.17M35.23M72.11M100.89M81.97M97.34M
Total Equity-12.98M244.27M163.54M492.99M354.70M601.15M
Cash40.81M230.56M153.43M451.86M205.40M499.18M
Total Debt26.80M19.17M55.16M75.38M63.78M-
Net Debt-14.02M-211.39M-98.27M-376.48M-141.63M-

Cash Flow

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-31.47M-55.11M-69.20M-114.81M-139.41M-132.31M
Investing Cash Flow-11.00K-548.00K-2.50M-28.56M-99.97M-
Financing Cash Flow57.81M245.42M-5.43M441.95M-7.49M-
Capital Expenditure0600.00K2.51M27.72M88.37M7.76M
Free Cash Flow-31.47M-55.71M-71.71M-142.52M-227.79M-140.07M
FCF to OCF100.00%101.09%103.63%124.14%163.39%105.87%

Key Statistics & Ratios

Market Cap18.72B
Enterprise Value14.75B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1478.76
Price / Book15.43
EPS-2.97
Book Value12.53
Revenue (TTM)0
Gross Profit (TTM)-3.45M
EBITDA-189.03M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-31.72%
Return on Assets-17.62%
Shares Outstanding80.68M
Shares Float62.73M
Beta0.13
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%